Oral manifestations of chronic graft-versus-host disease;Les manifestations buccales de la réaction du greffon contre l'hôte

Annales de Dermatologie et de Venereologie

Volumn 132, Issue 12, 2005, Pages 1017-1025

  Fricain, J C ^a   Sibaud, V ^b   Hafian, H ^c   Deminiere C ^a   Taieb A ^b   Boiron, J M ^d  

^a HÔPITAL PELLEGRIN   (France)

^b HÔPITAL SAINT ANDRÉ   (France)

^c REIMS UNIVERSITY HOSPITAL   (France)

^d HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN A; DEXAMETHASONE; IMMUNOSUPPRESSIVE AGENT; PILOCARPINE; PREDNISONE; PSORALEN; RETINOID; TACROLIMUS; THALIDOMIDE;

ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; HISTOPATHOLOGY; MOUTH DISEASE;

EID: 31844436210     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(05)79574-0     Document Type: Article

References (81)

1. Munker R, Schmid C, Madrigal JA, Kolb HJ. An update on graft-versus-host and graft versus-leukemia reactions: a summary of the sixth International Symposium held in Schloss Ellmau, Germany, January 22-24, 2004. Bone Marrow Transplant 2004;34:767-80.
2. Aractingi S, Carosella ED, Gluckman E. Manifestations cutanées de la réaction du greffon contre l'hôte. Ann Dermatol Venereol 1998;125:620-7
3. Johnson ML, Farmer ER. Graft-versus-host reactions in dermatology. J Am Acad Dermatol 1998;38:369-92; quiz 93-6.
4. Sanli H, Ekmeki P, Arat M, Gürman G. Clinical manifestations of cutaneous graft-versus-host disease after allogeneic haematopoietic cell transplantation: long term follow up results in a single turkish centre. Acta Derm Venereol 2004;84:296-01.
5. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect. 1966;62:21-78.
6. Dinulos JG, Levy ML. Graft-versus-host disease in children. Semin Dermatol 1995;14:66-9.
7. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324:667-74.
8. Sprent J, Surh CD, Agus D, Hurd M, Sutton S, Heath WR. Profound atrophy of the bone marrow reflecting major histocompatibility complex class II-restricted destruction of stem cells by CD4+ cells. J Exp Med 1994;180:307-17.
9. Sykes M, Harty MW, Szot GL, Pearson DA. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood 1994;83:2560-9.
10. Gilliam AC, Whitaker-Menezes D, Korngold R, Murphy GF. Apoptosis is the predominant form of epithelial target cell injury in acute experimental graft-versus-host disease. J Invest Dermatol 1996;107:377-83.
11. Sedghizadeh PP, Allen CM, Anderson KE, Kim DH, Kalmar JR, Lang JC. Oral graft-versus-host disease and programmed cell death: pathogenetic and clinical correlates. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;97:491-8.
12. Graubert TA, DiPersio JF, Russell JH, Ley TJ. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 1997;100:904-11.
13. Schmaltz C, Alpdogan O, Horndasch KJ, Muriglan SJ, Kappel BJ, Teshima T, et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 2001;97:2886-95.
14. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 1987;166:1280-9.
15. Hattori K, Hirano T, Miyajima H, Yamakawa N, Tateno M, Oshimi K, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 1998;91:4051-5.
16. Cooke KR, Hill GR, Gerbitz A, Kobzik L, Martin TR, Crawford JM, et al. Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation 2000;70:272-9.
17. Haimovitz-Friedman A, Cordon-Cardo C, Bayoumy S, Garzotto M, McLoughlin M, Gallily R, et al. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med 1997;186:1831-41.
18. Janin A, Deschaumes C, Daneshpouy M, Estaquier J, Micic-Polianski J, Rajagopalan-Levasseur P, et al. CD95 engagement induces disseminated endothelial cell apoptosis in vivo: immunopathologic implications. Blood 2002;99:2940-7.
19. Kansu E. The pathophysiology of chronic graft-versus-host disease. Int J Hematol 2004;79:209-15.
20. Vinzio S, Lioure B, Grunenberger F, Schlienger JL, Goichot B. Les manifestations d'allure auto-immune après allogreffe de moelle osseuse. Rev Med Interne 2004;25:514-23.
21. Anasetti C, Rybka W, Sullivan KM, Banaji M, Slichter SJ. Graft-v-host disease is associated with autoimmune-like thrombocytopenia. Blood 1989;73:1054-8.
22. Graze PR, Gale RP. Chronic graft versus host disease: a syndrome of disordered immunity. Am J Med 1979;66:611-20.
23. Wesierska-Gadek J, Penner E, Hitchman E, Kier P, Sauermann G. Nucleolar proteins B23 and C23 as target antigens in chronic graft-versus-host disease. Blood 1992;79:1081-6.
24. Parkman R. Clonal analysis of murine graft-vs-host disease. I. Phenotypic and functional analysis of T lymphocyte clones. J Immunol 1986;136:3543-8.
25. Dahllof G, Heimdahl A, Modeer T, Twetman S, Bolme P, Ringden O. Oral mucous membrane lesions in children treated with bone marrow transplantation. Scand J Dent Res 1989;97:268-77.
26. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson DE, Flournoy N, et al. Oral manifestations of chronic graft-v-host disease. Arch Intern Med 1984;144:1591-5.
27. Heimdahl A, Johnson G, Danielsson KH, Lonqvist B, Sundelin P, Ringden O. Oral condition of patients with leukemia and severe aplastic anemia. Follow-up 1 year after bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1985;60:498-504.
28. Thomas ED, Storb R, Cliff RA, Fefer A, Neiman PE, Lerner KG, et al. Bone marrow transplantation (second of two parts). N Engl J Med 1975;292:895-902.
29. Hsiao M, Schubert M, Thornquist M. Oral manifestations of acute graft-versus-host disease following marrow transplantation. J Dent Res Spec Issue. 1988;67:202-16.
30. Nakamura S, Hiroki A, Shinohara M, Gondo H, Ohyama Y, Mouri T, et al. Oral involvement in chronic graft-versus-host disease after allogeneic bone marrow transplantation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;82:556-63.
31. Hiroki A, Nakamura S, Shinohara M, Oka M. Significance of oral examination in chronic graft-versus-host disease. J Oral Pathol Med 1994;23:209-15.
32. Woo SB, Lee SJ, Schubert MM. Graft-vs.-host disease. Crit Rev Oral Biol Med 1997;8:201-16.
33. Barrett AP, Bilous AM. Oral patterns of acute and chronic graft-v-host disease. Arch Dermatol 1984;120:1461-5.
34. Franca CM, Domingues-Martins M, Volpe A, Pallotta Filho RS, Soares de Araujo N. Severe oral manifestations of chronic graft-vs.-host disease. J Am Dent Assoc 2001;132:1124-7.
35. Eggleston TI, Ziccardi VB, Lumerman H. Graft-versus-host disease. Case report and discussion. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:692-6.
36. Schubert MM, Sullivan KM. Recognition, incidence, and management of oral graft-versus-host disease. NCI Monogr 1990;135-43.
37. Garcia FVMJ, Pascual-Lopez M, Elices M, Dauden E, Garcia-Diez A, Fraga J. Superficial mucoceles and lichenoid graft versus host disease: report of three cases. Acta Derm Venereol 2002;82:453-5.
38. Campana F, Sibaud V, Chauvel A, Taieb A, Fricain JC. Oral superficial mucoceles associated with lichenoid disorders. J Oral Fac Maxillo Surg (accepté).
39. Janin-Mercier A, Devergie A, Arrago JP, Brocheriou C, Lemarchand-Venencie F, Rain JD, et al. Systemic evaluation of Sjögren-like syndrome after bone marrow transplantation in man. Transplantation 1987;43:677-9.
40. Sale GE, Shulman HM, Schubert MM, Sullivan KM, Kopecky KJ, Hackman RC, et al. Oral and ophthalmic pathology of graft versus host disease in man: predictive value of the lip biopsy. Hum Pathol 1981;12:1022-30.
41. Nagler R, Marmary Y, Krausz Y, Chisin R, Markitziu A, Nagler A. Major salivary gland dysfunction in human acute and chronic graft-versus-host disease (GVHD). Bone Marrow Transplant 1996;17:219-24.
42. Nagler RM, Laufer D, Nagler A. Parotid gland dysfunction in an animal model of chronic graft-vs-host disease. Arch Otolaryngol Head Neck Surg 1996;122:1057-60.
43. Nagler RM, Laufer D, Nagler A. Parotid gland dysfunction in a murine model of acute graft versus host disease [aGVHD]. Head Neck 1998;20:58-62.
44. Nagler RM, Nagler A. The effect of pilocarpine on salivary constituents in patients with chronic graft-versus-host disease. Arch Oral Biol 2001;46:689-95.
45. Nagler RM, Nagler A. The molecular basis of salivary gland involvement in graft-vs-host disease. J Dent Res 2004;83:98-103.
46. Bhatia S, Louie AD, Bhatia R.Solid cancers after bone marrow transplantation. J Clin Oncol 2001;19:464-7.
47. Socié G, Henry-Amar M, Bacigalupo A, Hous J, Tichelli A, Ljungran P.Malignant tumor occuring after treatment of aplastic anemia working party.N Engl J Med 1993;329:1152-7
48. Curtis R, Rowlings P, Deeg H, Shriner DA, Socié G, Travis LB. Solid cancers after bone marrow transplantation. N Engl J Med 1997;336:897-904.
49. Abdelsayed RA, Sumner T, Allen CM, Treadway A, Ness GM, Penza SL. Oral precancerous and malignant lesions associated with graft-versus-host disease: report of 2 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:75-80.
50. Szeto CH, Shek TW, Lie AK, Au WY, Yuen AP, Kwong YL. Squamous cell carcinoma of the tongue complicating chronic oral mucosal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2004;77:200-2.
51. Fricain JC, Campana F, Zwetyenga N, Deminière C, Marit G. Transformation carcinomateuse d'une lésion lichénoïde linguale de maladie chronique de réaction du greffon contre l'hôte. SFMBCB Beyrouth 2005.
52. Lishner M, Patterson B, Kandel R. Cutaneous and mucosal neoplasms in bone marrow transplant recipients. Cancer 1990;65:473-6.
53. Bradford CR, Hoffman HT, Wolf GT, Carey TE, Baker SR, McClatchey KD.Squamous cell carcinoma of the head and neck in organ transplant recipients:possible role of oncogenic viruses. Laryngoscope 1990;100:190-4.
54. Flowers ME, Doney KC, Storb R. Marrow transplantation for Fanconi anemia with or without leukemic transformation : an update of the seattle experience. Bone marrow Transplant 1992;9:167-73.
55. Otsubo H, Yokoe H, Miya T. Gingival squamous cell carcinoma in a patient with chronic graft versus host disease.Oral Surg, Oral Med, Oral Pathol, Oral Radiol Endod 1997;84:171-4.
56. Millen FJ, Rainey MG, Hows JN, Burton PA, Irvine GH, Swirsky D.Oral squamous cell carcinoma after allogeneic bone marrow transplantation for Fanconi anaemia. Br J Haematol 1997; 99:410-4.
57. Jansisyanont P, Pazoki A, Ord RA. Squamous cell carcinoma of the tongue after bone marrow transplantation in a patient with Fanconi's anemia.J Oral Maxillofac Surg 2000;58:1454-7.
58. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7
59. Fujiwara K, Sugiura J, Sakai Y. Electron microscopic studies of the early cellular events occurring in oral mucosa of rats affected by graft-versus-host disease (GVHD). J Oral Pathol Med 1997;26:90-2.
60. Nakhleh RE, Miller W, Snover DC. Significance of mucosal vs salivary gland changes in lip biopsies in the diagnosis of chronic graft-vs-host disease. Arch Pathol Lab Med 1989;113:932-4.
61. Mattsson T, Sundqvist KG, Heimdahl A, Dahllof G, Ljungman P, Ringden O. A comparative immunological analysis of the oral mucosa in chronic graft-versus-host disease and oral lichen planus. Arch Oral Biol 1992;37:539-47.
62. Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant. 2001;28:121-9.
63. Redding SW, Callander NS, Haveman CW, Leonard DL. Treatment of oral chronic graft-versus-host disease with PUVA therapy: case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:183-7.
64. Wolff D, Anders V, Corio R, Horn T, Morison WL, Farmer E, et al. Oral PUVA and topical steroids for treatment of oral manifestations of chronic graft-vs.-host disease. Photodermatol Photoimmunol Photomed 2004;20:184-90.
65. Elad S, Garfunkel AA, Shapira MY. Budesonide: a novel treatment for oral chronic graft versus host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:308-11.
66. Epstein JB, Reece DE. Topical cyclosporin A for treatment of oral chronic graft-versus-host disease. Bone Marrow Transplant 1994;13:81-6.
67. Fricain JC, Campana F, Hafian H, Jeandot J, Boiron JM. Intérêt de l'application locale de corticoïdes et de ciclosporine A dans le traitement des lésions buccales de la maladie de réaction du greffon contre l'hôte (GVHD). Med Buccale Chir Buccale 2004;10:49.
68. Epstein JB, Gorsky M, Epstein MS, Nantel N.Topical azathioprine in the treatment of immune-mediated chronic oral inflammatory conditions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:56-61.
69. Eckardt A, Starke O, Stadler M, Reuter C, Hertenstein B. Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus. Oral Oncol 2004;40:811-4.
70. Atkinson K, Weller P, Ryman W, Biggs J. PUVA therapy for drug-resistant graft-versus-host disease. Bone Marrow Transplant 1986;1:227-36.
71. Vogelsang GB, Wolff D, Altomonte V, Farmer E, Morison WL, Corio R, et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant 1996;17:1061-7.
72. Ménillo SA, Goldberg SL, Kierman P, Pecora AL. Intraoral psoralen ultraviolet A irradiation (PUVA) treatment of refractory oral chronic graft versus host disease following allogeneic stem cell transplantation. Bone Marrow Transplant 2001;28:807-8
73. Altman JS, Adler SS. Development of multiple cutaneous squamous cell carcinomas during PUVA treatment for chronic graft versus host disease. J Am Acad Dermatol 1994;31:505-7.
74. Greinix HT, Platzer BV, Rabitsh W, Gmeinhart B, Pineda CG, Kalhs P, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe aute and chronic graft versus host disease. Blood 1998;99:3098-4.
75. Child FJ, Ratnavel R, Watkins P, Samson D, Apperley J, Ball J, Taylor P,Russell-Jones R. Extracorporeal photophoresis (ECP)in the treatment of chronic graft versus host disease. Bone Marrow Transplant 1999;23:881-7.
76. Seaton ED, Szydlo RM, Kanfer E, Apperley JF, Russel-Jones R. Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft versus host disease and analysis of predictors of response. Blood 2003;102:1217-23.
77. Elad SH, Garfunkel AA, Enck CD, Dan Galili PhD, Or R. Ultraviolet B irradiation: A new therapeutic concept for the management of oral manifestations of graft versus host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;80:161-7.
78. Storb R, Prentice RL, Buckner CD, Clift RA, Appelbaum F, Deeg J, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 1983;308:302-7.
79. Einsele H, Ehninger G, Schneider EM, Kruger GF, Vallbracht A, Dopfer R, et al. High frequency of graft-versus-host-like syndromes following syngeneic bone marrow transplantation. Transplantation 1988;45:579-85.
80. Singhal S, Mehta J, Rattenbury H, Treleaven J, Powles R. Oral pilocarpine hydrochloride for the treatment of refractory xerostomia associated with chronic graft-versus-host disease. Blood 1995;85:1147-8.
81. Singhal S, Powles R, Treleaven J, Rattenbury H, Mehta J. Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies. Leuk Lymphoma 1997;24:539-43.